Advisors's mailing address filed with the SEC is 51 Astor Place, 10th Floor, New York, NY 10003, United States.
Over the last 5 years, insiders at Lyra Therapeutics have traded over $0 worth of Lyra Therapeutics stock and bought 19,620,470 units worth $85,899,322 . The most active insiders traders include Advisors Llcperceptive Life..., Edward T Anderson oraz Gp, Llcdamore Richard Anort.... On average, Lyra Therapeutics executives and independent directors trade stock every 76 days with the average trade being worth of $311,619. The most recent stock trade was executed by Harlan Waksal on 10 November 2023, trading 25,000 units of LYRA stock currently worth $74,000.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Lyra Therapeutics executives and other stock owners filed with the SEC include: